IL300387A - 6-mutated pyridazine compounds as SMARCA2 and/or SMARCA4 derivatives - Google Patents
6-mutated pyridazine compounds as SMARCA2 and/or SMARCA4 derivativesInfo
- Publication number
- IL300387A IL300387A IL300387A IL30038723A IL300387A IL 300387 A IL300387 A IL 300387A IL 300387 A IL300387 A IL 300387A IL 30038723 A IL30038723 A IL 30038723A IL 300387 A IL300387 A IL 300387A
- Authority
- IL
- Israel
- Prior art keywords
- phenyl
- cancer
- hydroxy
- alkyl
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041033326 | 2020-08-04 | ||
| PCT/IB2021/057089 WO2022029617A1 (en) | 2020-08-04 | 2021-08-03 | 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300387A true IL300387A (en) | 2023-04-01 |
Family
ID=80117730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300387A IL300387A (en) | 2020-08-04 | 2021-08-03 | 6-mutated pyridazine compounds as SMARCA2 and/or SMARCA4 derivatives |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12570650B2 (https=) |
| EP (1) | EP4192835A4 (https=) |
| JP (1) | JP2023536504A (https=) |
| KR (1) | KR20230061349A (https=) |
| CN (1) | CN116529250A (https=) |
| AU (1) | AU2021320052A1 (https=) |
| BR (1) | BR112023002089A2 (https=) |
| CA (1) | CA3188024A1 (https=) |
| IL (1) | IL300387A (https=) |
| MX (1) | MX2023001445A (https=) |
| WO (1) | WO2022029617A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| BR112022012410A2 (pt) | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| WO2025196686A1 (en) * | 2024-03-20 | 2025-09-25 | Aurigene Oncology Limited | Fused bicyclic compounds as smarca2 and/or smarca4 degraders |
| CN119874808B (zh) * | 2025-01-02 | 2026-04-17 | 四川大学 | 一种靶向smarca蛋白降解的化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017518348A (ja) * | 2014-06-20 | 2017-07-06 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | Ｉｒａｋ４阻害剤としての置換インダゾール化合物 |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017011371A1 (en) * | 2015-07-10 | 2017-01-19 | Arvinas, Inc | Mdm2-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| KR20190140438A (ko) * | 2017-02-28 | 2019-12-19 | 에피자임, 인코포레이티드 | 암 치료를 위한 smarca2의 저해 |
| US20190300521A1 (en) | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| US12371426B2 (en) | 2018-04-26 | 2025-07-29 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as SMARCA2/4 degraders |
| AU2021205326A1 (en) * | 2020-01-10 | 2022-07-21 | Amgen Inc. | SMARCA2-VHL degraders |
-
2021
- 2021-08-03 WO PCT/IB2021/057089 patent/WO2022029617A1/en not_active Ceased
- 2021-08-03 CN CN202180068383.4A patent/CN116529250A/zh active Pending
- 2021-08-03 AU AU2021320052A patent/AU2021320052A1/en active Pending
- 2021-08-03 US US18/019,721 patent/US12570650B2/en active Active
- 2021-08-03 IL IL300387A patent/IL300387A/en unknown
- 2021-08-03 CA CA3188024A patent/CA3188024A1/en active Pending
- 2021-08-03 BR BR112023002089A patent/BR112023002089A2/pt unknown
- 2021-08-03 MX MX2023001445A patent/MX2023001445A/es unknown
- 2021-08-03 KR KR1020237005345A patent/KR20230061349A/ko active Pending
- 2021-08-03 EP EP21852975.8A patent/EP4192835A4/en active Pending
- 2021-08-03 JP JP2023507923A patent/JP2023536504A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4192835A4 (en) | 2024-08-21 |
| US20240018134A1 (en) | 2024-01-18 |
| EP4192835A1 (en) | 2023-06-14 |
| JP2023536504A (ja) | 2023-08-25 |
| WO2022029617A1 (en) | 2022-02-10 |
| CN116529250A (zh) | 2023-08-01 |
| KR20230061349A (ko) | 2023-05-08 |
| MX2023001445A (es) | 2023-05-08 |
| BR112023002089A2 (pt) | 2023-02-28 |
| CA3188024A1 (en) | 2022-02-10 |
| AU2021320052A1 (en) | 2023-03-23 |
| US12570650B2 (en) | 2026-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12371426B2 (en) | Pyridazine derivatives as SMARCA2/4 degraders | |
| IL300387A (en) | 6-mutated pyridazine compounds as SMARCA2 and/or SMARCA4 derivatives | |
| EP4067344B1 (en) | Cycloalkyl urea derivative | |
| JP7762306B2 (ja) | 選択的ｐａｒｐ１阻害剤およびその用途 | |
| KR20210049895A (ko) | 고 활성 sting 단백질 작용제 화합물 | |
| WO2014134776A1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| US11352357B2 (en) | Cycloalkylurea derivative | |
| WO2019094552A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| EP4695250A1 (en) | Tetracyclic compounds as smarca2 and/or smarca4 degraders | |
| US20240398812A1 (en) | Modulators of trpml, their compositions and methods of use | |
| WO2021201036A1 (ja) | ヒドロキシピロリジン誘導体およびその医薬用途 | |
| JP2024502106A (ja) | ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用 | |
| EP2920154B1 (en) | Novel imidazol-piperidinyl derivatives as modulators of kinase activity | |
| EA052684B1 (ru) | 6-замещенные пиридазиновые соединения в качестве деструкторов smarca2 и/или smarca4 | |
| EP4476225A1 (en) | 3-substituted pyridazine compounds as smarca2 and/or smarca4 degraders | |
| AU2020360928A1 (en) | Azepan derivative | |
| WO2025094065A1 (en) | Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders | |
| WO2025196686A1 (en) | Fused bicyclic compounds as smarca2 and/or smarca4 degraders | |
| KR20250170567A (ko) | 치환된 아세틸렌 화합물 유도체 및 이의 약제학적 용도 | |
| WO2026080493A1 (en) | COMPOUNDS FOR THE TARGETED DEGRADATION OF PKA Cα | |
| HK40074199A (en) | Cycloalkyl urea derivative | |
| KR20260005897A (ko) | 신규 화합물 및 이의 용도 |